Results 21 to 30 of about 50,964 (281)

Pembrolizumab for a patient with metastatic castration‐resistant prostate cancer with microsatellite instability‐high

IJU Case Reports, 2020
Introduction We report the case of a patient with metastatic castration‐resistant prostate cancer with microsatellite instability‐high who was treated with pembrolizumab after cabazitaxel administration.
Motohiro Fujiwara, Yoshinobu Komai, Takeshi Yuasa, Noboru Numao, Shinya Yamamoto, Iwao Fukui, Junji Yonese   +6 more
doaj   +1 more source

Guidelines for Evaluating Treatment Response Based on Bone Scan for Metastatic Castration-Resistant Prostate Cancer: Prostate Cancer Clinical Trial Working Group 3 Recommendations

Journal of the Korean Society of Radiology, 2023
In prostate cancer, the bone is the most common site of metastasis, and it is essential to evaluate metastatic bone lesions to assess the tumor burden and treatment response.
Ji Sung Jang, Amy Junghyun Lee, Kye Jin Park, Kyung Won Kim, Hyo Jung Park   +4 more
doaj   +1 more source

Utility of plasma cell‐free DNA in metastatic castration‐resistant prostate cancer

IJU Case Reports, 2020
Introduction Cell‐free DNA is suggested as a prognostic biomarker in metastatic castration‐resistant prostate cancer. However, it remains unknown which parameter of cell‐free DNA is correlated with the progression and prognosis of metastatic castration ...
Itsuto Hamano, Shingo Hatakeyama, Tomoko Hamaya, Kyo Togashi, Teppei Okamoto, Hayato Yamamoto, Tohru Yoneyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Chikara Ohyama   +9 more
doaj   +1 more source

Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer. [PDF]

, 2013
BACKGROUND: Standard medical castration reduces muscle mass. We sought to characterize body composition changes in men undergoing maximal androgen suppression with and without exogenous gluocorticoids.
J S de Bono, Pezaro, C., Cassidy, A.M., de Bono, J.S., Pezaro, C, Seed, G., Mukherji, D, de Bono, JS, Omlin, A, Tunariu, N., N Tunariu, G Attard, D Olmos, Attard, G, G Seed, Reid, A.H.M., Seed, G, Mukherji, D., A M Cassidy, Bianchini, D., Cassidy, AM, Olmos, D., A H M Reid, Attard, G., A Omlin, D Bianchini, D Mukherji, Tunariu, N, Olmos, D, Reid, AHM, C Pezaro, Bianchini, D, Omlin, A.   +32 more
core   +1 more source

Bad expression influences time to androgen escape in prostate cancer [PDF]

, 2007
<b>OBJECTIVE</b>: To assess the role of selected downstream Bcl-2 family members (Bad, Bax, Bcl-2 and Bcl-xL) in the development of androgen-independent prostate cancer (AIPC), as androgen-deprivation therapy is the treatment of choice in ...
Teo, K., Traynor, P., Mukherjee, R., Edwards, J., Gemmell, L.   +4 more
core   +1 more source

Pinostilbene inhibits full-length and splice variant of androgen receptor in prostate cancer

Scientific Reports, 2023
Prostate cancer is the most prevalent cancer in men worldwide and is promoted by the sex hormone androgen. Expression of androgen from the testis can be significantly reduced through castration.
Won Sik Shin, Seung Hyun Han, Kyung Won Jo, Yunje Cho, Kyong-Tai Kim   +4 more
doaj   +1 more source

Visceral Disease in Castration-resistant Prostate Cancer [PDF]

European Urology, 2014
Metastatic involvement of the viscera in men with advanced castration-resistant prostate cancer (CRPC) has been poorly characterised to date. In 359 CRPC patients treated between June 2003 and December 2011, the frequency of radiologically detected visceral metastases before death was 32%.
Pezaro C. J., Omlin A., Lorente D., Nava Rodrigues D., Ferraldeschi R., Bianchini D., Mukherji D., Riisnaes R., Altavilla A., Crespo M., Tunariu N., De Bono J. S., Attard G.   +12 more
openaire   +3 more sources

Lutetium-177 Prostate-Specific Membrane Antigen-617 Treatment in Metastatic Castration-Resistant Prostate Adenocarcinoma: Results of Single-Center Experience

, 2023
Objective: Lutetium-177 prostate-specific membrane antigen-617 is a novel alternative therapeutic option in metastatic castration-resistant prostate cancer, especially useful for patients who do not respond to standard therapy methods.
Maman, Adem, Adem Maman
core   +1 more source

Efficacy of enzalutamide in patients with metastatic hormone-sensitive and castration-refractory prostate cancer: authors’ experience

Медицинский совет, 2021
Prostate cancer is one of the most common neoplasms in men. It currently ranks second in Russian Federation amongst male population in overall number of cases after only lung cancer and third in cancer mortality.
T. V. Ustinova, L. V. Bolotina, A. A. Paichadze, A. A. Kachmazov, A. A. Fedenko, A. D. Kaprin   +5 more
doaj   +1 more source

20(S)-protopanaxadiol inhibition of progression and growth of castration-resistant prostate cancer. [PDF]

PLoS ONE, 2014
Castration-resistant progression of prostate cancer after androgen deprivation therapies remains the most critical challenge in the clinical management of prostate cancer.
Bo Cao, Yanfeng Qi, Yan Yang, Xichun Liu, Duo Xu, Wei Guo, Yang Zhan, Zhenggang Xiong, Allen Zhang, Alun R Wang, Xueqi Fu, Haitao Zhang, Lijing Zhao, Jingkai Gu, Yan Dong   +14 more
doaj   +1 more source